ONCOFUCO-for Distributor and Healthcare Professional
We would like to explore potential partnerships in global market to make ONCOFUCO (former name Oligo Fucoidan) available to those who need it. We are interested in offering OliFuco® Oligo Fucoidan as a raw material or as a branded finished product to cater to the different markets’ unique needs.
Hi-Q has successfully developed a range of dietary supplement that utilize OliFuco® Oligo Fucoidan as a key ingredient, specifically for cancer patients as a complementary or adjunct therapy. These cancer dietary supplement products have been highly recommended by pharmacists and doctors, with over 3,500 pharmacies, hospitals, and clinics stocking and selling our dietary supplement products in Taiwan. Hi-Q’s products have also received excellent reviews and sales figures, highlighting the potential of these products in the market. The sales performance has been remarkable, and we believe that there is a great demand for such products in the global market.
Hi-Q ONCOFUCO (former name Oligo Fucoidan) series cancer dietary supplement products are highly recommended by doctors and health professionals, resulting in widespread adoption and availability in the market..
Hi-Q‘s products stand out as pharmacy hot-sellers, consistently topping the charts in over 3,000 pharmacies across Taiwan. With a sales history of over 14 years, we have earned the trust and preference of pharmacists, making us the go-to brand for cancer dietary supplements. This widespread popularity underscores the effectiveness and reliability of our products, reinforcing our commitment to providing top-quality solutions for our customers.
In the realm of healthcare, there exists a distinct division between medications and food. Cancer, undoubtedly, demands the comprehensive approach of medication and professional medical intervention. However, we firmly believe in the significant impact of nutritional support as a valuable adjunct to conventional cancer treatment. At the core of our philosophy lies the understanding that cancer dietary supplements, such as ours, serve as a bridge between pharmaceutical interventions and dietary needs. While medications address the disease at its core, we acknowledge the crucial role of tailored nutritional support in complementing and enhancing the therapeutic outcomes for cancer patients.
One significant milestone in our research journey occurred in 2017 when we successfully completed the first double-blind, randomized controlled trial at Kaohsiung Medical University. This landmark trial specifically evaluated the efficacy of OliFuco® as a supplemental therapy in metastatic colorectal cancer patients. The trial conclusively demonstrated the effectiveness of OliFuco® in enhancing the disease control rate among these patients. We are conducting ongoing studies
The scientific studies result show that Oligo fucoidan, whether through in vitro to in vivo research studies or clinical trials in humans, has been proven to produce positive bioactive and synergy effects of adjuvant therapy on cancer treatment. This allows molecular mechanisms in cancer research to be applied in adjunct cancer treatment, in line with the pursuit of translational medicine and the mindset of establishing a direct link between basic medical research and clinical applications
In 2023, Hi-Q won the esteemed NutraIngredients-Asia Award 2023: The 'Oscar' of Nutritional Ingredients Industry. Hi-Q was awarded the Nutrition Research Project Specialty Award for our project titled " Exploring the Adjunct Therapeutic Potential of OliFuco® Oligo Fucoidan in Supplemental Intervention for Cancer Cachexia: Enhancing Treatment Outcomes and Improving Quality of Life". This award-winning research project not only represents Hi-Q's outstanding contributions to the global nutrition industry but also provides cancer patients worldwide with more supplemental treatment options.
•Enhancing anti-tumor immune response
•Alleviating side effects of cachexia
•Improving quality of life
•Improving treatment tolerance of patients
